Blood-brain barrier efflux transport

Journal of Pharmaceutical Sciences

Volumn 92, Issue 9, 2003, Pages 1739-1753

  Golden, Pamela L ^a   Pollack, Gary M ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Blood brain barrier; Brain uptake; Efflux transport; Microdialysis; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTING POLYPEPTIDE TRANSPORTER; ORGANIC CATION TRANSPORTER; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANION TRANSPORT; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; CYTOLOGY; DRUG DEVELOPMENT; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM; LIPOPHILICITY; MICRODIALYSIS; MICROVASCULATURE; MOLECULAR BIOLOGY; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; SHORT SURVEY;

EID: 0041837255     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10424     Document Type: Short Survey

References (126)

1. Davson H. 1976. The blood-brain barrier. J Physiol 255:1-28.
2. Brightman MW. 1989. The anatomic basis of the blood-brain barrier. In: Neuwelt EA, editor. Implications of the blood-brain barrier and its manipulation, Volume 1. New York: Plenum Publishing Corporation, pp. 53-84.
3. Rubin LL, Staddon JM. 1999. The cell biology of the blood-brain barrier. Ann Rev Neurosci 22: 11-28.
4. Saunders NR, Habgood MD, Dziegelewska KM. 1999. Barrier mechanisms in the brain. I. Adult brain. Clin Exp Pharmacol Physiol 26:11-19.
5. Brightman MW. 1965. The distribution within the brain of ferritin injected into cerebral spinal fluid compartments. II. Parenchymal distribution. Am J Anat 117:193-220.
6. Reese TS, Karnovsky MJ. 1967. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207-217.
7. Sugiyama Y, Kusuhara H, Suzuki H. 1999. Kinetics and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in drug delivery to the brain. J Controlled Release 62:179-186.
8. El-Bacha RS, Minn A. 1999. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol 45:15-23.
9. Noé B, Hagenbuch B, Stieger B, Meier PJ. 1997. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
10. Gao B, Stieger B, Noé B, Fritschy J-M, Meier PJ. 1999. Localization of the organic anion transporting polypeptide 2 (oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1263.
11. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, Yawo H. 1998. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem 273:22395-22410.
12. Hosoya K, Asaba H, Terasaki T. 2000. Brain-to-blood efflux transport of estrone-3-sulfate at the blood-brain barrier in rats. Life Sci 67:2699-2711.
13. Asaba H, Hosoya K, Takagana H, Ohtsuki S, Tamura E, Takizawa T, Terasaki T. 2000. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J Neurochem 75:1907-1916.
14. Hosoya K, Sugawara M, Asaba H, Terasaki T. 1999. Blood-brain barrier produces significant efflux of L-aspartic acid, but not D-aspartic acid: In vivo evidence using the brain efflux index method. J Neurochem 73:1206-1211.
15. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. 1999. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16:904-908.
16. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporter mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
17. Kakyo M, Sakagami H, Nishio T, Nakai D, Nakagomi R, Tokui T, Naitoh T, Matsuno S, Abe T, Yawo H. 1999. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Lett 445:343-346.
18. Gao B, Hagenbuch B, Kullak-Ublick G, Benke D, Aguzzi A, Meier PJ. 2000. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
19. Angeletti RH, Novikoff PM, Juvvadi SR, Fritschy JM, Meier PJ, Wolkoff AW. 1997. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 94:283-286.
20. Villalobos AR, Parmelee JT, Pritchard JB. 1997. Functional characterization of choroid plexus epithelial cells in primary culture. J Pharmacol Exp Ther 282:1109-1116.
21. Suzuki H, Sawada Y, Sugiyama Y, Iga T, Hanano M. 1986. Transport of cimetidine by the rat choroid plexus in vitro. J Pharmacol Exp Ther 239:927-935.
22. Whittico MT, Gang YA, Giacomini KM. 1990. Cimetidine transport in isolated brush border membrane vesicles from bovine choroid plexus. J Pharmacol Exp Ther 255:615-623.
23. 2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776-32786.
24. Chen A-Y, Yu C, Bodley A, Peng F, Liu LF. 1993. A new mammalian DMA topoisomerase I poison Hoechst 33342: Cytotoxicity and drug resistance in human cell cultures. Cancer Res 53:1332-1337.
25. Zamora JM, Pearce HL, Beck WT. 1988. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454-462.
26. Seelig A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252-261.
27. Seelig A, Landwojtowicz E. 2000. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
28. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
29. Jetté L, Béliveau R. 1993. P-glycoprotein is strongly expressed in brain capillaries. In: Drewes LR, Betz AL, editors. Frontiers in cerebral vascular biology. New York: Plenum Press, pp. 121-125.
30. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51:1427-1437.
31. Pardridge WM, Golden PL, Kang YS, Bickel U. 1997. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 68:1278-1285.
32. Golden PL, Pardridge WM. 2000. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 20: 165-181.
33. Decléves X, Regina A, Laplanche J-L, Roux F, Boval B, Launay J-M, Scherrmann J-M. 2000. Functional expression of P-glycoprotein and multidrug resistance-associated protein (mrpl) in primary cultures of rat astrocytes. J Neurosci Res 60: 594-601.
34. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900-3905.
35. Wijnholds J, de Lange ECM, Scheffer GL, van den Berg DJ, Mol CAAM, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. 2000. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105(3):279-285.
36. 2,5] enkephalin in mdr1a-gene deficient mice. J Pharmacol Exp Ther 287:545-552.
37. Lovecamp T, Cooper PS, Hardison J, Bryant SD, Guerrini R, Balboni G, Salvadori S, Lazarus LH. 2001. Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent δ-opioid antagonist. Brain Res 902:131-134.
38. Callaghan R, Riordan JR. 1993. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268:16059-16064.
39. Thompson SJ, Koszdin K, Bernards CM. 2000. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92:1392-1399.
40. Galliard PJ, van der Sandt ICJ, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. 2000. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res 17:1198-1205.
41. Aquilante CL, Letrent SP, Pollack GM, Brouwer KLR. 1999. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:47-51.
42. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
43. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W. 2000. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36:66-74.
44. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, Vaalburg W, Franssen EJF. 1998. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
45. Luker GD, Rao VV, Crankshaw CL, Dahlheimer J, Piwnica-Worms D. 1997. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochem 36: 14218-14227.
46. Marquardt D, McCrone S, Center MS. 1990. Mechanisms of multidrug resistance in HL60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50:1426-1430.
47. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
48. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. 1994. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833-4836.
49. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SPC, Deeley RG, Keppler D. 1996. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314:433-437.
50. Seelig A, Blatter XL, Wohnsland F. 2000. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther 38:111-121.
51. Loe DW, Almquist KC, Deeley RG, Cole SPC. 1996. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682.
52. Loe DW, Deeley RG, Cole SPC. 1998. Characterization of vincristine transport by the 190 kDa multidrug resistance protein, MRP: Evidence for co-transport with reduced glutathione. Cancer Res 58:5130-5136.
53. Renes J, De Vries EGE, Nienhuis EF, Jansen PLM, Muller M. 1999. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug-resistance protein MRP1. Br J Pharmacol 126:681-688.
54. Seetharaman S, Barrand MA, Maskell L. Scheper RJ. 1998. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 70:1151-1159.
55. Huai-Yan H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW. 1998. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Comm 243:816-820.
56. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. 1998. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 285:1260-1265.
57. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergman R, Couraud RP, Roux F. 1998. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715.
58. Zhang Y, Han HY, Elmquist WF, Miller DW. 2000. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876:148-153.
59. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. 2001. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 162: 181-191.
60. Strazielle N, Ghersi-Egea J-F. 1999. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci 19:6275-6289.
61. Gutmann H, Török M, Fricker G, Huwyler J, Belinger C, Drewe J. 1999. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Met Dispos 27:937-941.
62. Takakura Y, Audus KL, Borchardt RT. 1992. Cultured brain microvessel endothelial cells as in vitro models of the blood-brain barrier. NIDA Res Monogr 120:138-152.
63. Takakura Y, Audus KL, Borchardt RT. 1992. Blood-brain barrier: transport studies in isolated brain capillaries and in cultured brain endothelial cells. Adv Pharmacol 22:137-165.
64. Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T. 1993. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug resistance transporter, P-glycoprotein. Biochem Pharmacol 46:1096-1099.
65. Fontaine M, Elmquist WF, Miller DW. 1996. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci 59:1521-1531.
66. Huwyler J, Drewe J, Gutmann H, Thole M, Fricker G. 1998. Modulation of morphine-6-glucuronide penetration into the brain by P-glycoprotein. J Clin Pharmacol Ther 36:69-70.
67. Takanaga H, Murakami H, Koyabu N, Matsuo H, Naito M, Tsuruo T, Sawada Y. 1998. Efflux transport of tolbutamide across the blood-brain barrier. J Pharm Pharmacol 50:1027-1033.
68. Henthorn TK, Liu Y, Mahapatro M, Ng KY. 1999. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 289:1084-1089.
69. Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. 1999. Contribution of bunitrolol to efflux across the blood-brain barrier. Biopharm Drug Dispos 20:85-90.
70. Murata M, Tamai I, Kato H, Nagata O, Tsuji A. 1999. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther 290:51-57.
71. Ichikawa N, Naora K, Hirano H, Hashimoto M, Masumura S, Iwamoto K. 1996. Isolation and primary culture of rat cerebral microvascular endothelial cells for studying drug transport in vitro. J Pharmacol Toxicol Meth 36:45-52.
72. Van Gelder W, Cleton-Soeteman MI, Huijskes-Heins MI, van Run PR, van Eijk HG. 1997. Transcytosis of 6.6-nm gold-labeled transferrin: An ultrastructural study in cultured porcine blood-brain barrier endothelial cells. Brain Res 746: 105-116.
73. Biegel D, Spencer DD, Pachter JS. 1995. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res 692:183-189.
74. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. 1992. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267:20383-20391.
75. Johnson MD, Anderson BD. 1999. In vitro models of the blood-brain barrier to polar permeants: Comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. J Pharm Sci 88:620-625.
76. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer K, Brouwer KLR. 1999. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 58:951-957.
77. Wolburg H, Neuhaus J, Kniesel U, Krauss B, Schmid EM, Ocalan M, Farrell C, Risau W. 1994. Modulation of tight junction structure in blood-brain barrier endothelial cells. Effects of tissue culture, second messengers and cocultured astrocytes. J Cell Sci 107:1347-1357.
78. Goldstein GW. 1988. Endothelial cell-astrocyte interactions. A cellular model of the blood-brain barrier. Ann NY Acad Sci 529:31-39.
79. Yamagata K, Tagami M, Nara Y, Mitani M, Kubota A, Fujino H, Numano F, Kato T, Yamori Y. 1997. Astrocyte-conditioned medium enhances blood-brain barrier properties in endothelial cells. Clin Exp Pharmacol Physiol 24:710-713.
80. Regina A, Romero IA, Greenwood J, Adamson P, Bourre JM, Couraud PO, Roux F. 1999. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem 73:1954-1963.
81. Keppler D, Cui Y, Konig J, Leier I, Nies A. 1999. Export pumps for anionic conjugates encoded by MRP genes. Adv Enzyme Reg 39:237-246.
82. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ. 1998. The sister of P-glycoprotein represents the canalicular bile salt export pump. J Biol Chem 273:10046-10050.
83. Schuetz EG, Yasuda K, Arimori K, Schuetz JD. 1998. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin. But not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350:340-347.
84. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. 1994. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.
85. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC, Deeley RG. 1997. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 52:344-353.
86. Eveers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. 1998. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319.
87. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
88. Song S, Suzuki H, Kawai R, Tanaka C, Akasaka I, Sugiyama Y. 1998. Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26:1128-1133.
89. Golden PL, Brouwer KR, Pollack GM. 1993. Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis. Pharm Res 10:1765-1771.
90. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
91. Zong J, Pollack GM. 2000. Modulation of morphine antinociception by P-glycoprotein activity and expression in mice. Pharm Res 17:749-753.
92. Desrayaud S, Guntz P, Scherrmann JM, Lemaire M. 1997. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 61:153-163.
93. 2,5]enkephalin by P-glycoprotein modulation. Pharm Res 16:296-301.
94. Oldendorf WH. 1970. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 24:372-376.
95. Oldendorf WH. 1974. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 147:813-816.
96. Cornford EM, Diep CP, Pardridge WM. 1985. Blood-brain barrier transport of valproic acid. J Neurochem 44:1541-1550.
97. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. 1972. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178:984-986.
98. Begley DJ, Squires LK, Zlokovic BV, Mitrovic DM, Hughes CC, Revest PA, Greenwood J. 1990. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem 55:1222-1230.
99. Oldendorf WH. 1971. Brain uptake of metabolites and drugs following carotid arterial injections. Trans Am Neurol Assoc 96:46-50.
100. Pardridge WM, Landaw EM, Miller LP, Braun LD, Oldendorf WH. 1985. Carotid artery injection technique: Bounds for bolus mixing by plasma and by brain. J Cerebral Blood Flow Metab 5:576-583.
101. Cornford EM, Braun LD, Crane PD, Oldendorf WH. 1978. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 103:1297-1303.
102. Cornford EM, Young D, Paxton JW, Sofia RD. 1992. Blood-brain barrier penetration of felbamate. Epilepsia 33:944-954.
103. Unger C, Eibl H, von Heyden HW, Kim DJ, Nagel GA. 1986. Aminoglutethimide: Penetration of the blood brain barrier. Invest New Drugs 4:237-240.
104. Guillot F, Misslin P, Lemaire M. 1993. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 21:339-346.
105. Unger C, Eibl H, von Heyden HW, Krisch B, Nagel GA. 1985. Blood-brain barrier and the penetration of cytostatic drugs. Klin Wochenschrift 63:565-571.
106. Kakee A, Terasaki T, Sugiyama Y. 1996. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559.
107. Kakee A, Terasaki T, Sugiyama Y. 1997. Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: In vivo evidence by use of the brain efflux index method. J Pharmacol Exp Ther 283:1018-1025.
108. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y. 1997. P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580.
109. Takasato Y, Rappaport SI, Smith QR. 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247: H484-H493.
110. Smith QR. 1996. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism, Volume 8. New York: Plenum Press, pp. 285-307.
111. Smith QR, Takasato Y. 1986. Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann NY Acad Sci 481:186-201.
112. Deguchi Y, Nozawa K, Yamada Y, Kimura R. 1997. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: Possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther 280:551-560.
113. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. 1997. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 49:80-88.
114. Dagenais C, Rousselle C, Pollack GM, Scherrmann J-M. 2000. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cerebral Blood Flow Metab 20:381-386.
115. de Lange EC, Danhof M, de Boer AG, Breimer DD. 1997. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies of drug transport across the blood-brain barrier. Brain Res Brain Res Rev 25:27-49.
116. Wang Q, Yang H, Miller DW, Elmquist WF. 1995. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem Biophys Res Comm 211: 719-726.
117. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. 1999. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27:827-834.
118. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. 1999. The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 128:563-568.
119. de Lange EC, de Bock G, Schinkel AH, de Boer AG, Breimer DD. 1998. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 15:1657-1665.
120. Hammarlund-Udenaes M, Paalzow LK, de Lange EC. 1997. Drug equilibration across the blood-brain barrier. Pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134.
121. Morgan ME, Singhal D, Anderson BD. 1996. Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther 277:1167-1176.
122. Golden PL, Pollack GM. 1998. Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain. Biopharm Drug Dispos 19:263-272.
123. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
124. Didier AD, Loor F. 1995. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 63:263-267.
125. Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. 1998. Effect of GW918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15:599-605.
126. Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, Eichelbaum M. 1997. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 72:261-267.